Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.61
- Piotroski Score 3.00
- Grade Market Outperform
- Symbol (ELEV)
- Company Elevation Oncology, Inc.
- Price $0.61
- Changes Percentage (4.21%)
- Change $0.02
- Day Low $0.57
- Day High $0.62
- Year High $5.83
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $9.00
- High Stock Price Target $10.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.85
- Trailing P/E Ratio -4.15
- Forward P/E Ratio -4.15
- P/E Growth -4.15
- Net Income $-45,704,000
Income Statement
Quarterly
Annual
Latest News of ELEV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Chaotic Sydney train shutdown averted after eleventh hour crisis talks with union
Sydney's train network narrowly avoided a shutdown as the government agreed to run 24-hour services, meeting rail union demands. Talks led to the strike being called off, averting disruptions to all t...
By The Guardian | 15 hours ago -
Exclusive | Soaring some 900 feet above NYC, the highest-elevated home on Fifth...
Penthouse 80 at 520 Fifth Ave. is the highest-elevated home along Fifth Avenue, listed for $9.95 million. Offering stunning 360-degree views of Manhattan, this two-bedroom residence boasts luxurious f...
By New York Post | 1 day ago -
'I'm abandoned': Seniors trapped by broken elevator in Vancouver's West End - BC | Globalnews.ca
Seniors in a Vancouver apartment building have been without elevator service for over a month, leaving them stranded. Residents, like Nicholas Lebessis, with mobility issues, are unable to leave their...
By Global News | 1 day ago
